You are here: Industry Insights > Oncolytic virus

News List

AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration prnasia
April 20, 2021
On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting.
First person enrolled in Phase I oncolytic virus trial europeanpharmaceuticalreview
March 04, 2021
The Phase I/IIa trial of BT-001 will assess the safety and efficacy of the virus’ dual mode of action in solid tumours.
Vyriad signs a contract with IBM to build an oncolytic virus anti-cancer vaccines manufacturing facility biospectrumasia
May 14, 2018
The custom buildout will be financed with proceeds from a recently completed $9 million secured convertible note financing...
Johnson & Johnson pens $140M deal for preclinical oncolytic virus startup fiercebiotech
May 03, 2018
Johnson & Johnson is paying $140 million upfront to buy oncolytic immunotherapy startup BeneVir Biopharm.The outlay gives J&J control of preclinical prospects designed to evade the body’s immune system...
DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401 americanpharmaceuticalreview
December 07, 2017
DNAtrix announced the intratumoral delivery of DNX-2401 to the first pediatric patient in a Phase 1 study for diffuse intrinsic pontine glioma (DIPG).